India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests Veracyte, Inc. (Nasdaq: VCYT), a ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. This voice experience is generated by AI. Learn more. This voice ...

Prostate cancer affects one in five Australian men, making it the most common cancer in the country. Now, researchers at the ...

Prostate cancer screening plans could be scaled back even further, despite growing calls for more testing to be rolled out.

Source: Getty Images Investigators analyzed exfoliated cells in urine specimens to identify 50 candidate RNAs for prostate cancer detection. Serum PSA testing is not specific to prostate cancer, and ...